These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30458999)

  • 1. Co-administration of saponin quil A and PRRSV-1 modified-live virus vaccine up-regulates gene expression of type I interferon-regulated gene, type I and II interferon, and inflammatory cytokines and reduces viremia in response to PRRSV-2 challenge.
    Charerntantanakul W; Pongjaroenkit S
    Vet Immunol Immunopathol; 2018 Nov; 205():24-34. PubMed ID: 30458999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saponin Quil A up-regulates type I interferon-regulated gene and type I and II interferon expressions which are suppressed by porcine reproductive and respiratory syndrome virus.
    Charerntantanakul W; Fabros D
    Vet Immunol Immunopathol; 2018 Jan; 195():76-83. PubMed ID: 29249322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral supplementation of quercetin in PRRSV-1 modified-live virus vaccinated pigs in response to HP-PRRSV-2 challenge.
    Ruansit W; Charerntantanakul W
    Vaccine; 2020 Apr; 38(19):3570-3581. PubMed ID: 32184034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Supplementation of
    Ruansit W; Charerntantanakul W
    Front Immunol; 2022; 13():929338. PubMed ID: 35924249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response and protective efficacy of intramuscular and intradermal vaccination with porcine reproductive and respiratory syndrome virus 1 (PRRSV-1) modified live vaccine against highly pathogenic PRRSV-2 (HP-PRRSV-2) challenge, either alone or in combination with of PRRSV-1.
    Madapong A; Saeng-Chuto K; Chaikhumwang P; Tantituvanont A; Saardrak K; Pedrazuela Sanz R; Miranda Alvarez J; Nilubol D
    Vet Microbiol; 2020 May; 244():108655. PubMed ID: 32402335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Membrane-Bound Interleukin-15 as an Immunomodulatory Adjuvant Enhances NK and γδ T Cell Responses and Confers Heterologous Protection.
    Cao QM; Ni YY; Cao D; Tian D; Yugo DM; Heffron CL; Overend C; Subramaniam S; Rogers AJ; Catanzaro N; LeRoith T; Roberts PC; Meng XJ
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29643245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity.
    Martelli P; Gozio S; Ferrari L; Rosina S; De Angelis E; Quintavalla C; Bottarelli E; Borghetti P
    Vaccine; 2009 Jun; 27(28):3788-99. PubMed ID: 19442420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphocyte activation as cytokine gene expression and secretion is related to the porcine reproductive and respiratory syndrome virus (PRRSV) isolate after in vitro homologous and heterologous recall of peripheral blood mononuclear cells (PBMC) from pigs vaccinated and exposed to natural infection.
    Ferrari L; Martelli P; Saleri R; De Angelis E; Cavalli V; Bresaola M; Benetti M; Borghetti P
    Vet Immunol Immunopathol; 2013 Feb; 151(3-4):193-206. PubMed ID: 23228653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses and protection by vaccine and various vaccine adjuvant candidates to virulent porcine reproductive and respiratory syndrome virus.
    Charerntantanakul W; Platt R; Johnson W; Roof M; Vaughn E; Roth JA
    Vet Immunol Immunopathol; 2006 Jan; 109(1-2):99-115. PubMed ID: 16165219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of PRRSV-2 MLV vaccines administrated via the intramuscular or intradermal route and evaluation of PRRSV transmission upon needle-free and needle delivery.
    Madapong A; Saeng-Chuto K; Tantituvanont A; Nilubol D
    Sci Rep; 2021 Nov; 11(1):23107. PubMed ID: 34845289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs.
    Kristensen CS; Kvisgaard LK; Pawlowski M; Holmgaard Carlsen S; Hjulsager CK; Heegaard PMH; Bøtner A; Stadejek T; Haugegaard S; Larsen LE
    Vaccine; 2018 Jan; 36(2):227-236. PubMed ID: 29191738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.
    Van Noort A; Nelsen A; Pillatzki AE; Diel DG; Li F; Nelson E; Wang X
    Virol J; 2017 Apr; 14(1):76. PubMed ID: 28403874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a DNA-launched replicon as a vaccine for porcine reproductive and respiratory syndrome virus.
    Pujhari S; Baig TT; Hansra S; Zakhartchouk AN
    Virus Res; 2013 May; 173(2):321-6. PubMed ID: 23353778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-protection of a modified-live porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine against a heterologous PRRSV-1 challenge in late-term pregnancy gilts.
    Jeong J; Park C; Oh T; Park KH; Yang S; Kang I; Park SJ; Chae C
    Vet Microbiol; 2018 Sep; 223():119-125. PubMed ID: 30173737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant.
    Dwivedi V; Manickam C; Patterson R; Dodson K; Murtaugh M; Torrelles JB; Schlesinger LS; Renukaradhya GJ
    Vaccine; 2011 May; 29(23):4058-66. PubMed ID: 21419162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-mediated immune response and protective efficacy of porcine reproductive and respiratory syndrome virus modified-live vaccines against co-challenge with PRRSV-1 and PRRSV-2.
    Madapong A; Saeng-Chuto K; Boonsoongnern A; Tantituvanont A; Nilubol D
    Sci Rep; 2020 Feb; 10(1):1649. PubMed ID: 32015495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs.
    Fontanella E; Ma Z; Zhang Y; de Castro AM; Shen H; Halbur PG; Opriessnig T
    Vaccine; 2017 Jan; 35(1):125-131. PubMed ID: 27876202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A porcine reproductive and respiratory syndrome virus candidate vaccine based on the synthetic attenuated virus engineering approach is attenuated and effective in protecting against homologous virus challenge.
    Evenson D; Gerber PF; Xiao CT; Halbur PG; Wang C; Tian D; Ni YY; Meng XJ; Opriessnig T
    Vaccine; 2016 Nov; 34(46):5546-5553. PubMed ID: 27742217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs.
    Kim T; Park C; Choi K; Jeong J; Kang I; Park SJ; Chae C
    Clin Vaccine Immunol; 2015 Jun; 22(6):631-40. PubMed ID: 25855554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing neutralizing antibody production by an interferon-inducing porcine reproductive and respiratory syndrome virus strain.
    Wang R; Xiao Y; Opriessnig T; Ding Y; Yu Y; Nan Y; Ma Z; Halbur PG; Zhang YJ
    Vaccine; 2013 Nov; 31(47):5537-43. PubMed ID: 24063978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.